The U.S. boom in biotech IPOs has largely failed to drift across the Atlantic and galvanize many floats in Europe, but France’s OSE Pharma is looking to buck that trend in hopes of bankrolling late-stage studies for its immuno-oncology candidate.

…read more

Source: French immuno-oncology biotech OSE eyes an EU IPO


0 No comments